1. Home
  2. NERV vs OPP Comparison

NERV vs OPP Comparison

Compare NERV & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

N/A

Current Price

$4.43

Market Cap

231.1M

Sector

Health Care

ML Signal

N/A

Logo RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

OPP

RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

N/A

Current Price

$7.45

Market Cap

190.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
NERV
OPP
Founded
2007
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
231.1M
190.4M
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
NERV
OPP
Price
$4.43
$7.45
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.50
N/A
AVG Volume (30 Days)
132.9K
88.6K
Earning Date
05-01-2026
01-01-0001
Dividend Yield
N/A
14.41%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$41,175,600.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.93
$7.40
52 Week High
$12.46
$8.77

Technical Indicators

Market Signals
Indicator
NERV
OPP
Relative Strength Index (RSI) 49.84 33.37
Support Level $3.87 N/A
Resistance Level $4.73 $8.03
Average True Range (ATR) 0.33 0.08
MACD -0.03 -0.01
Stochastic Oscillator 19.49 12.50

Price Performance

Historical Comparison
NERV
OPP

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.

Share on Social Networks: